- Home
- BGR vs DCTH Comparison
BGR vs DCTH Comparison
Compare BGR & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGR
- DCTH
- Stock Information
- Founded
- BGR 2004
- DCTH 1988
- Country
- BGR United States
- DCTH United States
- Employees
- BGR N/A
- DCTH N/A
- Industry
- BGR Trusts Except Educational Religious and Charitable
- DCTH Medical/Dental Instruments
- Sector
- BGR Finance
- DCTH Health Care
- Exchange
- BGR Nasdaq
- DCTH Nasdaq
- Market Cap
- BGR 345.4M
- DCTH 398.2M
- IPO Year
- BGR N/A
- DCTH N/A
- Fundamental
- Price
- BGR $13.47
- DCTH $14.31
- Analyst Decision
- BGR
- DCTH Strong Buy
- Analyst Count
- BGR 0
- DCTH 4
- Target Price
- BGR N/A
- DCTH $22.25
- AVG Volume (30 Days)
- BGR 73.3K
- DCTH 411.6K
- Earning Date
- BGR 01-01-0001
- DCTH 11-08-2024
- Dividend Yield
- BGR 6.02%
- DCTH N/A
- EPS Growth
- BGR N/A
- DCTH N/A
- EPS
- BGR 0.69
- DCTH N/A
- Revenue
- BGR N/A
- DCTH $22,644,000.00
- Revenue This Year
- BGR N/A
- DCTH $1,605.13
- Revenue Next Year
- BGR N/A
- DCTH $111.67
- P/E Ratio
- BGR $18.97
- DCTH N/A
- Revenue Growth
- BGR N/A
- DCTH 945.91
- 52 Week Low
- BGR $11.38
- DCTH $3.70
- 52 Week High
- BGR $13.37
- DCTH $14.47
- Technical
- Relative Strength Index (RSI)
- BGR 66.12
- DCTH 70.27
- Support Level
- BGR $13.00
- DCTH $12.14
- Resistance Level
- BGR $13.50
- DCTH $12.98
- Average True Range (ATR)
- BGR 0.17
- DCTH 0.77
- MACD
- BGR 0.09
- DCTH 0.16
- Stochastic Oscillator
- BGR 91.67
- DCTH 95.12
About BGR BlackRock Energy and Resources Trust
BlackRock Energy & Resources Trust is a closed-end equity fund providing total return through a combination of current income, gains and capital appreciation by investing in equity securities and derivatives of energy and natural resources companies. The fund invests in various sectors such as information technology, financials, healthcare, consumer discretionary, industrial, energy, materials and utilities.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.